Daniel H. Palmer

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi et al. · Journal of Clinical Oncology · 2014 · 2.8K citations · Full text

Medicine, Oncology, Clinical Epidemiology +16

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

John P. Neoptolemos, Deborah Stocken, Claudio Bassi et al. · JAMA · 2010 · 1.4K citations

Medicine, Oncology, Pharmacotherapy +17